Partnering Interest In Infectious Disease Space Showing Promise Beyond HCV Hotspot
Executive Summary
Antiviral agents and vaccines for indications beyond the red-hot hepatitis C indication highlight the infectious diseases track at this year’s Therapeutic Area Partnerships conference.
You may also be interested in...
Biota To Become U.S. Company Through Merger With Nabi
Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.
Agenus Extends Cash Runway In GSK Partnership Expansion
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.